Recommended the Issuance of Bonus Issue, subject to shareholders approval and any other applicable regulatory and statutory approval, in the ratio of 1:4 .i.e. 1(one) new Fully paid up Equity Shares of Rs. 2/- for every 4 (Four) existing Fully paid up Equity Shares of Rs. 2/- held by eligible member as on record date, which shall be announce in due course.
Corporate Action-Board recommends Bonus Issue
Filed with BSE · · 6 pages · English
Summary by 6ix AI
Titan Biotech Limited's board has approved a bonus share issuance to equity shareholders, subject to shareholder approval at the upcoming Annual General Meeting. The board also approved an increase in the company's authorized share capital and recommended the re-appointment of an independent director for an additional term. The Annual General Meeting is scheduled for a specific date, with details regarding the cut-off and record dates provided for shareholders. This filing serves to inform stakeholders of significant corporate actions taken by the board during their recent meeting.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Titan Biotech
- Board Meeting Outcome for Outcome Of Board Meeting Dated September 3, 2026
- Titan Biotech Limited Press Release Aug 31 2026
- Closure of Trading Window
- Titan Biotech Limited Press Release Aug 14 2026
- Announcement under Regulation 30 (LODR)-Newspaper Publication
Later from Titan Biotech
- Corporate Action-Fixes Book Closure For 34Th Annual General Meeting Of The Company
- Fixation Of Annual General Meeting Date, Record Date, Book Closure Date And E-Voting Date
- Intimation Of Record Date For The Purpose Of Final Dividend
- Titan Biotech Limited Press Release Sep 03 2026
- Titan Biotech Limited Press Release Sep 04 2026
Follow Titan Biotech into a list and get an email when it puts out news.
Follow Titan Biotech